Navigation Links
Data Published in Proceedings of National Academy of Sciences Highlights Potential of Micromet's BiTE Antibody Platform
Date:6/29/2010

against tumor cells, and represent a new therapeutic approach to cancer therapy. Typically, antibodies cannot engage T cells because T cells lack the appropriate receptors for binding antibodies. BiTE antibodies have been shown to bind T cells to tumor cells, ultimately inducing a self-destruction process in the tumor cells referred to as apoptosis, or programmed cell death. In the presence of BiTE antibodies, T cells have been demonstrated to serially eliminate tumor cells, which explains the activity of BiTE antibodies at very low concentrations. Through the killing process, T cells start to proliferate, which leads to an increased number of T cells at the site of attack.

About Micromet, Inc.

Micromet, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibody-based therapies for the treatment of cancer. Its product development pipeline includes novel antibodies generated with its proprietary BiTE® technology, as well as conventional monoclonal antibodies. Two of Micromet's BiTE antibodies and three of its conventional antibodies are currently in clinical trials. Micromet has collaborations with a number of leading pharmaceutical and biotechnology companies, including sanofi-aventis, Bayer Schering Pharma, Merck Serono, Boehringer Ingelheim, MedImmune and Nycomed. Additional information can be found at www.micromet-inc.com.

Safe Harbor

This press release contains forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained herein which do not
'/>"/>

SOURCE Micromet, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
2. Adlyfe Study on the Detection of Misfolded Proteins Published in the Journal Transfusion
3. Nebivolol Lowers Blood Pressure in Mild-to-Moderate Hypertensive Patients as Demonstrated in a Study Published in the Journal of Clinical Hypertension
4. Results from Study Evaluating PROCRIT(R) in Intensive Care Unit Patients Published in New England Journal of Medicine
5. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
6. Study Published in Endocrinology Reports Potential of Modigene Technology to Extend Duration of Protein Drugs
7. New Data Published in Neurology Show Once-Daily Lamictal XR Significantly Reduced Partial Seizures in Patients with Epilepsy
8. Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine
9. Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
10. UPDATE: Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
11. Tumor Eradication Article Published by Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... , Aug. 28, 2015 ... has announced the addition of the "Investigation ... to their offering. Developed by Pharmacia ... prostaglandin receptor agonist which effectively reduces intraocular pressure. ... FDA, latanoprost (under the trade name of Xalatan) ...
(Date:8/28/2015)... HONG KONG , August 28, 2015 ... Gero in collaboration with one of the leading academics ... Reis (current world record holder in life extension for ... new insights into biology of aging and age-related diseases, primarily, ... networks. The work has just been published as "Stability analysis ...
(Date:8/28/2015)... Perrigo Company plc ("Perrigo") (NYSE: PRGO ... (NASDAQ: MYL ) shareholder vote regarding its planned ... of Mylan,s offer to Perrigo shareholders have always been, ... careful reflection of the value available to Perrigo shareholders, ... Mylan has allowed its shareholders to consider," said ...
Breaking Medicine Technology:China Latanoprost Market Investigation Report 2015-2019 2Gero: Physics Meets Biology to Help Defeat Aging 2Gero: Physics Meets Biology to Help Defeat Aging 3Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 3Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 4Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 5
(Date:8/28/2015)... ... August 28, 2015 , ... Joining a ... Memorial Hospital recently transitioned management companies to partner with Wound Care Advantage (WCA) ... outpatient wound center. , Transitioning wound care management providers can be a ...
(Date:8/28/2015)... ... August 28, 2015 , ... Approximately 2,000 United Methodists ... celebrate children helping children, a thank you to the many creative and generous ... to the United Methodist initiative to end malaria deaths. , The Columbus Zoo ...
(Date:8/28/2015)... ... , ... An article published August 19th by the LA Times ... to open a pizzeria in Westchester. Mr. LaRocco was aware from opening prior pizza ... the current process, having already gone on for over a year, is taking much ...
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... For Dallas, ... is taking part with their subsidiary USPI Tenet Health. , The American Heart Association ... heart disease and stroke. They believe that together, a difference can be made. Walkers ...
(Date:8/28/2015)... Baltimore, MD (PRWEB) , ... August 28, 2015 , ... ... reduction system from Merz, received FDA clearance for results that last for two ... clearance is exciting news for patients who are looking for a long-lasting, effective solution ...
Breaking Medicine News(10 mins):Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 3Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 4Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 2Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 3Health News:Article on Building Approval Process for LA Business Highlights the Need for a Bridge Between Businesses and City Officials, says Fire Protection Group Inc. 2Health News:North Central Surgical Center’s Subsidiary Participates in Walk 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 3
... 1, WASHINGTON, May 1 U.S. Paralympian April ... on the track. In September, she,will travel to Beijing ... favored to medal in the 100- and 200-meter dashes. ... well what working,Americans need to do to keep their ...
... notes, "We make,decisions for the right reasons and then we ... the right time, by the right people, and at the,right ... Management has now grown so much that an increasingly,sophisticated system ... and strategic at its core -- but that is fraught ...
... ... HILLS, Ill. and CORPUS CHRISTI, Texas, May 1 ... from Texas,A&M-Corpus Christi,s Kinesiology Department demonstrated the correlation,between improved ... improvement in the hitting performance of,Islander baseball players after ...
... Texas Cardiac Arrhythmia Recruits and Hires Dr. Andrea ... Executive Medical Director of the Texas Cardiac Arrhythmia,Institute ... May 1 St. David,s HealthCare,along with Texas ... Cardiac Arrhythmia Institute (TCAI) at St. David,s Medical ...
... N.C., May 1 The Oregon State,Supreme Court ... statewide class,action in which plaintiff sought to make ... for medical monitoring of all Oregon,cigarette smokers., ... of the complaint and,the intermediate appellate court,s unanimous ...
... hinder a protein called IGF-1 not entirely successful, studies ... idea that prostate cancer can be treated successfully just ... growth factor (IGF-1) has been undermined by two new ... by a number of drug companies and academic researchers, ...
Cached Medicine News:Health News:U.S. Paralympian April Holmes Teams With LIFE Foundation to Encourage Americans to Assess Their Disability Insurance Needs This May 2Health News:U.S. Paralympian April Holmes Teams With LIFE Foundation to Encourage Americans to Assess Their Disability Insurance Needs This May 3Health News:U.S. Paralympian April Holmes Teams With LIFE Foundation to Encourage Americans to Assess Their Disability Insurance Needs This May 4Health News:Best Practices in Designing Effective Brand Teams 2Health News:Study by Texas A&M University-Corpus Christi Confirms Training With Vision Software Enhances Hitting Skills 2Health News:St. David's HealthCare and Texas Cardiac Arrhythmia Announce International Center For Training, Research and Treatment of Heart Rhythm Disorders 2Health News:St. David's HealthCare and Texas Cardiac Arrhythmia Announce International Center For Training, Research and Treatment of Heart Rhythm Disorders 3Health News:St. David's HealthCare and Texas Cardiac Arrhythmia Announce International Center For Training, Research and Treatment of Heart Rhythm Disorders 4Health News:Complications Found in Proposed Prostate Cancer Treatment 2
Bipolar Atrial "J" Lead...
Unipolar Atrial "J" Lead...
The VascoTip J 9/60 PU is a unipolar tined, J-preformed permanent pacing lead. Due to advanced technology, VascoTip J 9/60 PU M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm),...
The VascoTip J 9/60 PU is a unipolar tined, J-preformed permanent pacing lead. Due to advanced technology, VascoTip J 9/60 PU M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm),...
Medicine Products: